Skip to main content

Share story

Science

Suppressing crosstalk for Rydberg quantum gates

Suppressing crosstalk for Rydberg quantum gates Image: Primary
Scientists have introduced a technique for reducing crosstalk in the implementation of controlled-Z gates on neutral atom quantum computers that use local laser addressing. A fraction of the light applied to target atoms typically reaches neighboring atoms, leading to errors in the quantum operations. The analysis focused on a configuration with two atoms undergoing the gate and a third atom affected by the leaked light. Through perturbative methods, the team constructed a gate protocol modeled on spin-echo techniques. This design eliminates the primary contribution to amplitude errors that arise from the crosstalk. Numerical simulations of the protocol show an improvement in gate fidelity by two orders of magnitude. The enhancement holds across many parameter values typical of current experimental setups. To address any leftover phase errors, the researchers also created a compensating circuit. The work demonstrates that the protocol can suppress the leading order amplitude error. Results indicate that local addressing can support high-fidelity quantum gates on Rydberg-based quantum computers.
Sources
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Quantum Journal and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.